Change language :

Français

Investors

Events & presentations

Acomplia® Update

  • To print this page, please use the File menu or press simultaneously ctrl + p keys.
  • Send this page

November 5, 2008

On November 5, 2008, sanofi-aventis announced the discontinuation of all clinical trials with rimonabant.
At a conference call on October 23, 2008, the sanofi-aventis management reviewed its decision to suspend the marketing authorisation of Acomplia® in obese and overweight patients, complying with the EMEA’s recommendation.

 

Download documents

Recorded audio webcast held on October 23, 2008

Euronext Paris (SAN)

Quote: €42.82. Level change: +1.15%
Last update: July 03, 2009 05.35 PM (CET)

NYSE (SNY)

Quote: $29.66. Level change: 0%
Last update: July 02, 2009 04.54 PM (EST)

Subscriptions